17.08.2022 /
Pentixapharm publishes positive Phase II data on Pentixafor PET diagnostics
OMEICOS Therapeutics Announces Positive Phase 2 Study Outcome Demonstrating OMT-28’s Potential in Primary Mitochondrial Diseases (PMD)
Eckert & Ziegler on Track as Planned and Achieves Another Record Year in 2025
